The level of amyloid (white shades in area encircled by green dotted lines) – the protein thought to drive neurodegeneration in AD, is high in the brain of AD mouse (left) and reduces after the administration of the genome editing therapy throughout the brain (right).
An international research team led by scientists from the Hong Kong University of Science and Technology (HKUST) has developed a novel strategy using brain-wide genome-editing technology that can reduce Alzheimer’s disease (AD) pathologies in genetically modified AD mouse models. This advanced technology offers immense potential to be translated as a novel long-acting therapeutic treatment for AD patients.
In China alone, over 500,000 patients are estimated to be living with a hereditary form of AD – familial Alzheimer’s disease (FAD), which is a congenital form of AD highly associated with family history. Although FAD has a clear genetic cause and can be diagnosed before cognitive problems occur, no effective treatment currently exists.
There is enormous potential in the use of genome-editing technology1 as therapeutic strategies for diseases caused by inherited mutations, such as FAD. It is especially useful for correcting disease-causing genetic mutations before symptoms appear, for which it is considered a “once-and-for-all” treatment as its effects can last a lifetime. However, several hurdles have prevented its clinical development and application – most notably the lack of an effective, efficient, and non-invasive means to deliver genome-editing agents into the brain. Furthermore, existing genome-editing technologies are unable to generate beneficial outcomes throughout the whole brain.
Recently, a team led by Prof. Nancy Ip, Vice-President for Research and Development at HKUST, developed a new genome-editing system that not only crosses the blood–brain barrier, but also delivers an optimized genome-editing tool to the entire brain. Using a newly engineered delivery vehicle for genome-editing, this strategy achieves efficient brain-wide genome editing through a single non-invasive intravenous administration. This effectively disrupts FAD-inflicted mutations in AD mouse models and ameliorates AD pathologies throughout the entire brain, paving the way to novel therapeutic development for the disease.
Meanwhile, the research team also found in the mouse models that the level of amyloid, a protein thought to drive neurodegeneration in AD, remained low for 6 months post-treatment (about 1/3 of their normal lifespan), demonstrating that this single-shot genome-editing strategy has lasting effects. More importantly, no side effects were detected so far in the mice.
“As the first demonstration of efficient brain-wide genome editing to alleviate Alzheimer’s disease pathology throughout the whole brain, this is really an exciting development,” said Prof. Ip, who is also the Morningside Professor of Life Science and Director of the State Key Laboratory of Molecular Neuroscience at HKUST. “Our work is an important milestone for the use of genome editing in treating hereditary brain diseases, and contributes to the development of precision medicine for inherited forms of neurodegenerative diseases.”

This research was a collaborative effort among scientists from HKUST; the California Institute of Technology; and the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. The results were recently published in Nature Biomedical Engineering.
Original Article: HKUST Scientists Develop Genome-editing Strategy for Potential Alzheimer’s Disease Therapy
More from: Hong Kong University of Science and Technology | California Institute of Technology | Chinese Academy of Sciences
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Brain-wide genome-editing
- Using CRISPR to Lift the Lid on Probiotics
In this interview, we speak to Echo Pan, a Ph.D. student from North Carolina State University about her latest research that used CRISPR to uncover more on probiotics.
- Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board
"We are honored to have Dr. Church, a pioneer in the fields of genome engineering ... evolving science of gene editing offers tremendous opportunities to address a wide range of diseases using ...
- Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the ...
- Tissue nanotransfection technology proves useful in non-viral topical gene editing to close complex cutaneous wounds
TNT-based gene editing technology can remove that barrier.” In this study, genome-wide methylation was observed ... crushed nerve and the stroke-affected brain. This is the first time promoter ...
- Tissue nanotransfection technology proves useful in non-viral topical gene editing to close complex cutaneous wounds
TNT-based gene editing technology can remove that barrier." In this study, genome-wide methylation was observed ... crushed nerve and the stroke-affected brain. This is the first time promoter ...
Go deeper with Google Headlines on:
Brain-wide genome-editing
Go deeper with Bing News on:
Genome editing
- CRISPR Gene Editing Market Size is projected to reach USD 14.80 Billion by 2030, growing at a CAGR of 29.80%: Straits Research
The global CRISPR Gene Editing Market was valued USD 1.09 billion in 2021 and is predicted to reach USD 14.80 billion by 2030, increasing at a CAGR of 29.80% from 2022 to 2030. North America dominated ...
- High Cholesterol CRISPR Cure Enters Human Trial
New CRISPR based gene therapy aims to permanently deactivate a gene in the liver that regulates the production of PCSK9, a protein that prevents the body from removing excess cholesterol. In trials ...
- Gene Editing Tools Market are slated to top US$ 481.3 Million in 2029
According to latest research by FMI, the global gene editing tools market is estimated to have accounted for more than US$ 481.3 Mn in terms of value in 2022. The report on the gene editing tools ...
- Genome Editing Market 2022 Deep Analysis of Key Vendor in the Market Revenue Focus On Price Trends -2027
A new report of Market Research Update titled “Genome Editing Market Analysis 2022-2027” is a detailed sketch of the business sphere in terms of current and future trends driving the profit matrix.
- Intellia Therapeutics Is Pushing CRISPR-Based Therapy Forward, Slowly But Surely
Intellia’s recent data from its Regeneron collaboration for CRISPR-based NTLA-2001 shows a durable response to the lead in vivo genome editing candidate.